Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is Expected to Grow at a CAGR over ~ 4.4 % from 2017 to 2023
Methicillin-resistant Staphylococcus aureus (MRSA) is an antibiotic resistant strains of the pathogen. MRSA infections are classified as hospital-acquired (HA-MRSA) or community-acquired (CA-MRSA). MRSA causes infections such as skin infections, bone and joint infections, bacteremia, animal infections and others.
According to bulletin of the atomic scientists, about 10 million people in the US (3.6 percent of the population) are immune-compromised. The World Health Organization estimated that about 36.7 million people had HIV/AIDS worldwide in 2016. Thus, the rising immune-compromised population is expected to propel the market growth over the review period. Additionally, growing geriatric population projected to support the growth of the market since older people are more susceptible to MRSA infections. World Health Organization estimated that during 2015-2050, the proportion of the world's population will be nearly double from 12% to 22% and by 2020, the number of people aged over 60 years likely to outnumber children younger than 5 years.
Another strong driver is growing concerns of MRSA infections and increasing government support to curb MRSA. For example, hospital readmissions reduction program established under Affordable Care Act (ACA) financially penalizes hospitals if they have higher than expected 30-day readmission rates for diseases such as pneumonia. The recommendations of the committee has resulted in hospital readmissions national priority and a direct financial incentive to reduce readmissions. The financial incentives for reducing readmissions and the rising cost of non-compliance is expected to benefit the Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market.
High cost of novel drug therapy and low healthcare expenditure in developing regions projected to hamper the growth of the market over the review period. Moreover, patent expiry is also expected to lower the market value due to generic competition. For example, Pfizer’s Zyvox and Merck’s Cubicin, used for the treatment of MRSA have lost patents in major markets and their patent for alternative formulations and chemical forms is threatened by imminent patent expiry dates, which is expected to lower the market due to competition from generics and greater market fragmentation.
Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Players
Some of the key players profiled in the report are Merck KGaA, Olon, Allergan, Baxter, Theravance Biopharma, Pfizer, Mylan N.V, Novartis, and others.
The global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market has been segmented on the basis of drug class, MRSA types, disease indications, and end user.
Based on the drug class, the market has been segmented as sulfa drugs, tetracyclines, oxazolidinones, glycopeptide antibiotics, and other.
Based on the MRSA types, the market has been segmented as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA).
Based on the disease indications, the market has been segmented as skin infections, bone and joint infections, bacteremia, animal infections, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Access Complete Report @ https://www.marketresearchfuture.com/reports/mrsa-drugs-market-2102
The prominent players in the global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market are Merck KGaA (UK), Olon (Italy), Allergan (Dublin, Ireland), Baxter (US), Theravance Biopharma (Theravance Biopharma), Pfizer (US), Mylan NV (US), and Novartis (Switzerland).
Some of the key strategies followed by players operating in the global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market were innovation, product development, and acquisition & mergers.
- Americas showed high demand for the high-end MRSA drugs products due to broader market size and higher spending power.
- China is expected to be one of the top three fastest-growing markets for MRSA drugs shortly.
- Merck KGaA and Pfizer PLC are some of the prominent market players in the global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market.
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Market Research Future
+1 646 845 9312